ImmunOs Therapeutics AG is a pre-clinical biotechnology company focused on discovering and developing first-in-class novel human immunomodulatory proteins against cancer.
ImmunOs Therapeutics AG
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/immunos-therapeutics-ag” connections=”true” suffix=””]
ImmunOs Therapeutics has discovered a novel family class of immunomodulators that stimulate the immune system and increase the efficacy of check-point antibodies (CTLA4 + PD-1) in combinatorial therapies. The designed antibodies targets diverse receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses.
In Dec 2017, ImmunOs Therapeutics raised 2.3 Mn CHF financing round to advance clinical development.